<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526549</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-304</org_study_id>
    <nct_id>NCT03526549</nct_id>
  </id_info>
  <brief_title>Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite)</brief_title>
  <official_title>A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835
      lasts in the treatment of Cellulite.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who lose their response as compared to Day 71 of EN3835-302/303</measure>
    <time_frame>60 months</time_frame>
    <description>Measured by proportion of subjects that both the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) scores/ratings return to baseline of the double-blind studies (EN3835-302/303) or worse; both CR-PCSS and PR-PCSS worsened 2-levels compared to the score at Day 71 of the double-blind studies (EN3835-302/303); either CR-PCSS or PR-PCSS worsened 2-levels compared to the scores at Day 71 of the double-blind studies (EN3835-302/303); both CR-PCSS and PR-PCSS scores worsened by 1-level compared to the corresponding scores at Day 71 of the double-blind studies (EN3835-302/303)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the PR-PCSS</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 5 levels, 0=None to 4=Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the CR-PCSS</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 5 levels, 0=None to 4=Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Patient Reported Cellulite Impact Scale (PR-CIS) from Baseline (Day 1) of EN3835-302/303</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 11 levels; 0=Not at All to 10=Extremely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the Subject Satisfaction with cellulite treatment</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 5 levels; -2=Very dissatisfied to +2=Very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects at each level of improvement in the subject self-rating scale</measure>
    <time_frame>60 months</time_frame>
    <description>Scale is 7 levels; 0=Extremely dissatisfied to 6=Extremely satisfied</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>EN3835 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN3835</intervention_name>
    <description>Collagenase Clostridium Histolyticum (CCH)</description>
    <arm_group_label>EN3835 Active</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        All Subjects (Through Day 180):

          1. Voluntarily sign and date an informed consent agreement

          2. Have participated in and completed the double-blind Phase 3 study EN3835-302 or
             EN3835-303

          3. Be willing to apply sunscreen to the buttocks before each exposure to the sun while
             participating in the study

          4. Be judged to be in good health

          5. Be willing and able to cooperate with the requirements of the study

          6. Be able to read, complete and understand the patient reported outcomes rating
             instruments in English.

        In addition to inclusion Criteria for All Subjects Through Day 180, additional Inclusion
        Criteria are listed below:

        Inclusion Criteria - Category I Subjects:

          1. Received active EN3835 in study EN3835-302 or EN3835-303

          2. Maximum composite response at Day 71 in either or both buttocks in double-blind study
             EN3835-302 or EN3835-303 was ONLY a 1-level improvement on CR-PCSS/PR-PCSS

        Inclusion Criteria - Category II Subjects:

          1. Received active EN3835 in study EN3835-302 or EN3835-303

          2. Maximum composite response at Day 71 in either or both buttocks in double-blind study
             EN3835-302 or EN3835-303 was at least a 2-level composite improvement on
             CR-PCSS/PR-PCSS

        Inclusion Criteria - Category III Subjects:

        1. Received active EN3835 in study EN3835-302 or EN3835-303 but did not meet eligibility
        criteria for Category I or Category II status

        Inclusion Criteria - Retreatment Subjects (Eligible Category I and Category II Subjects
        Whom opt to Receive Retreatment):

        1. Have a negative serum pregnancy test

        Exclusion Criteria

        All Subjects (Through Day 180):

          1. Intends to or has used any of the local applications/therapies/injections/procedures
             that restricts study participation

          2. Intends to use tanning spray or tanning booths during this period

          3. Has received or intends to receive an investigational drug or treatment, other than
             the treatment received in study EN3835-302/303 during this period

          4. Any other condition(s) that, in the Investigator's opinion, might indicate the subject
             to be unsuitable for the study

        In addition to Exclusion Criteria for All Subjects Through Day 180, additional Exclusion
        Criteria also apply to Category I and Category II subjects:

        Exclusion Criteria - Category I and Category II Subjects (Post Day 180):

        1. Has received any collagenase treatments at any time since completion of the double-blind
        study (EN3835-302 or EN3835-303).

        Exclusion Criteria for Subjects Whom opt for Observations Only (ie, no retreatment): None

        Exclusion Criteria - Category II Subjects:

        Exclusion criteria for Subjects Whom opt for Observation Only (ie, no retreatment): None

        Exclusion Criteria - Category III Subjects: None

        Exclusion Criteria - Retreatment Subjects (Eligible Category I and Category II Subjects
        Whom opt to Receive Retreatment):

          1. Has systemic conditions (coagulation disorders, malignancy, keloidal scar, adnormal
             wound healing) that restricts study participation

          2. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active
             infection/inflammation, skin laxity, flaccidity and/or skin sagging, active cutaneous
             alteration, tattoo/mole) that restricts study participation

          3. Requires anticoagulant or antiplatelet medication during the study

          4. Prior to and during the course of retreatment (Treatment Visit 1 through Treatment
             Visit 4), is nursing or providing breast milk in any manner

          5. Prior to and during the course of retreatment (Treatment Visit 1 through Treatment
             Visit 4), intends to become pregnant during the study

          6. Prior to and during the course of retreatment (Treatment Visit 1 through Treatment
             Visit 4), intends to use tanning spray or tanning booths during the study

          7. Has received an investigational drug or treatment, other than treatment in study
             EN3835-302/303, within 30 days before retreatment with study drug

          8. Has a known systemic allergy to collagenase or any other excipient of study drug

          9. Has received any collagenase treatments at any time since completion of the
             double-blind study

         10. Any other condition(s) that, in the Investigator's opinion, might indicate the subject
             to be unsuitable for Category II retreatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McLane, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #11</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #41</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #14</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #9</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #35</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #42</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #17</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #39</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #23</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #38</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #8</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #40</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #27</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #36</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #20</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #19</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #34</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #30</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #16</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #25</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #10</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #33</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #18</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #4</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #24</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #32</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #12</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #15</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #29</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #26</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #5</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #22</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #6</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #13</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #7</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #28</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #21</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #37</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #31</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

